Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02515097 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis
A Phase 3 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 213
- Enrollment target
NCT02515097 is a Phase 3 study that has completed, run by Bausch Health Americas. The registered enrollment target is 213 participants.
The verdict
NCT02515097, a Phase 3 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 213 participants
- Enrollment target
Study Summary
This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment \[IGA\] score of 3 or 4).
Interventions
- DRUG IDP-122 Lotion
- DRUG IDP-122 Vehicle Lotion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2015-11-05 |
| Est. Completion | 2017-03-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02515097
The ClinicalTrials.gov registry entry for NCT02515097 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 213 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IDP-122 Lotion is the first listed.
NCT02515097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02515097 about?
NCT02515097 is a clinical study titled "Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis". This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment \[IGA\] score of 3 or 4).
What is the current status of trial NCT02515097?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 213 participants. The study started on 2015-11-05. Estimated completion is 2017-03-15.
What interventions are being tested in trial NCT02515097?
The interventions under investigation include: IDP-122 Lotion (DRUG), IDP-122 Vehicle Lotion (DRUG).
Who is sponsoring clinical trial NCT02515097?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.